TUMOR IMAGING
GALLIUM-67 CITRATE AND SESTAMIBI
- Tumour of Primary Unknown
- Disease burden (Extend of tumour) with whole body imaging
- Residual tumour activity post therapy
- Recurrent tumour activity in the midst of post- surgical/ therapeutic changes
- Determine sites of biopsy (most metabolic active site)
- Lymphomas
- Benign – Sarcoidiosis; Idiopathic lung disease
NEUROENDOCRINE TUMOURS
- Radiolabelled MIBG (meta-iodo-benzyl-guaindine) and radiolabelled Octreotide for diagnostic imaging and for therapeutic purposes
WELL-DIFFERENTIATED THYROID CARCINOMA
- Radioiodine has 3 main indications in the postoperative management of patients with thyroid cancer: Ablation of residual thyroid tissue with 131-I
- Imaging for possible recurrent disease with 123-I or 131-I
- And treatment of residual or recurrent thyroid cancer with 131-I
- Chylothroax